Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Gynecologic Cancer

Gynecologic Cancer

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

The abstract concludes: 
This is the first surgical study demonstrating a meaningful survival benefit in OC: Surgery in pts with first relapse and TFIp of 6+ mos and selected by a positive AGO-Score resulted in a significant increase of OS, PFS and TFST with acceptable morbidity and, therefore, should be offered to suitable pts. The benefit was exclusively seen in pts with CR indicating the importance of both the optimal selection of pts (eg. by AGO score) and of centres with expertise and a high chance of achieving a CR. Clinical trial information: NCT01166737
 
————————————————————————————————————————————————————————
 
6001 A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.
 
Rongyu Zang, Jianqing Zhu, Tingyan Shi, et al.
 
The abstract concludes: 
SCR in selected pts resulted in a dramatically significant extension of PFS. The interim analysis of TFSa indicate that SCR might contribute to long-term survival.
————————————————————————————————————————————————————————
 
6002 Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
 
Andres Poveda, Anne Floquet, Jonathan A. Ledermann, et al.
 
The abstract concludes: 
In the final analysis of SOLO2, maintenance olaparib provided an unprecedented improvement of 12.9 months in median OS vs placebo. This is the first study with olaparib tablets, and the first since Study 19 (NCT00753545), to provide long-term follow-up and final OS data in pts with PSROC and a BRCAm. Clinical trial information: NCT01874353
 
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————
 
6003 A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
 
Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, et al.
 
The abstract concludes: 
C+O demonstrated similar activity to SOC in relapsed plat-sensitive ovca but did not meet the primary endpoint of improved PFS. Clinical trial information: NCT02446600
————————————————————————————————————————————————————————
 
6004 Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.
 
Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, et al.
 
The abstract concludes: 
The combination of MIRV with BEV demonstrates an encouraging ORR with a favorable tolerability profile in pts with recurrent ovarian cancer regardless of platinum sensitivity, particularly in those with tumors that express high levels of FRα. Clinical trial information: NCT02606305
————————————————————————————————————————————————————————
 
6005 Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
 
Ursula A. Matulonis, Roni Shapira, Alessandro Santin, et al. 
 
The abstract concludes: 
Pembro monotherapy was associated with modest antitumor activity in pts with recurrent AOC. There appeared to be a trend toward increased ORR with higher PD-L1 expression in both cohorts. Responses were durable and typically lasted ≥6 months. Median OS was 18.7 months overall, with a trend toward a longer OS with increasing PD-L1 expression in both cohorts. No new safety signals were identified. Clinical trial information: NCT02674061
————————————————————————————————————————————————————————
 
6006 Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.
 
Vincent Balaya, Benedetta Guani, Laurent Magaud, et al.
 
The abstract concludes: 
SLN biopsy alone is oncologically safe in early-stage cervical cancer. Full lymphadenectomy could be omitted in case of bilateral negative SLN. Worse prognosis was associated with higher FIGO stage disease.
————————————————————————————————————————————————————————
 
6007 Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.
 
He Huang, Yanling Feng, Ting Wan, Yanna Zhang, et al.
 
The abstract concludes: 
In this trial, sequential chemoradiation, rather than concurrent chemoradiation, resulted in a higher disease-free survival and lower risk of cancer death than radiation alone among women with early-stage cervical cancer after radical surgery. Clinical trial information: NCT00806117
————————————————————————————————————————————————————————
 
LBA6008 Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.
 
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, Jet al.
 
The abstract concludes: 
TROPHIMMUN is the first trial of immunotherapy in GTT patients. The anti-PD-L1 monoclonal antibody avelumab was effective, with a favorable safety profile compared to chemotherapy, in patients with resistance to mono-chemotherapy. About 50 % patients could be cured of their chemoresistant diseases. Avelumab may be a new therapeutic option. Clinical trial information: NCT03135769.
 
————————————————————————————————————————————————————————
 
Kedar Kirtane, Erminia Massarelli, Glenn J. Hanna, et al.
 
The abstract concludes:
This study is currently open and accruing patients. Clinical trial information: NCT03912831.
————————————————————————————————————————————————————————
 

101 Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.

Scott Norberg, Nisha Nagarsheth, Andrew Sinkoe, et al. 

The abstract concludes:

E7 TCR-T cells demonstrated safety and clinical activity in the treatment of highly refractory metastatic HPV-16+ cancers. Treatment resistance was linked to definitive genetic defects in the targeted peptide-HLA complex and to manifold defects in antigen processing and interferon response. Clinical trial information: NCT02858310

————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Clinical Science Symposium
Learning from the Biology: Advances in Endometrial and Ovarian Cancer
Poster Discussion Session
Gynecologic Cancer
 
Poster Session
Gynecologic Cancer
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Gynecologic (Abstracts #6001, 6005, LBA6008)
Access Content Now